Document is current
Any future updates will be listed below
-
Authors
O’Dell, Ryan S.
Mecca, Adam P.
Chen, Ming-Kai
Naganawa, Mika
Toyonaga, Takuya
Lu, Yihuan
Godek, Tyler A.
Harris, Joanna E.
Bartlett, Hugh H.
Banks, Emmie R.
Kominek, Victoria L.
Zhao, Wenzhen
Nabulsi, Nabeel B.
Ropchan, Jim
Ye, Yunpeng
Vander Wyk, Brent C.
Huang, Yiyun
Arnsten, Amy F. T.
Carson, Richard E.
van Dyck, Christopher H. http://orcid.org/0000-0003-1779-097X
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01AG052560, R01AG062276, P50AG047270, RF1AG057553, K23AG057794)
Dana Foundation
National Center for Advancing Translational Sciences (UL1 TR001863)
Thomas P. Detre Fellowship Award in Translational Neuroscience Research in Psychiatry
Ruth L. Kirschstein National Research Service Award, Clinical Neuroscience Research Training in Psychiatry (T32 2T32MH019961-21A1)
- License Information
-
More Information
Article History
Received: 8 September 2020
Accepted: 7 December 2020
First Online: 5 January 2021
Ethics approval and consent to participate
: This study was approved by the Yale University Human Investigation Committee and the Yale Radioactive Drug Research Committee. In compliance with the Declaration of Helsinki, written informed consent was obtained from all participants and their study partners/caregivers prior to study participation.
: All participants and study partners/caregivers gave written informed consent to participate in this investigational PET study for scientific purposes, including publications. The informed consents are available from the corresponding author upon reasonable request. All reported data are anonymized, and no individual participant information can be identified from the presented datasets.
: APM, REC, and CHvD report grants from National Institutes of Health for the conduct of the study. APM reports grants for clinical trials from Genentech and Eisai outside the submitted work. MKC reports research support from the Dana Foundation and research support from Eli Lilly and clinical trials from Merck outside the submitted work. YH reports research grants from the UCB and Eli Lilly outside the submitted work. YH, NBN, and REC have a patent for a newer version of the tracer. REC is a consultant for Rodin Therapeutics and has received research funding from UCB. REC reports having received grants from AstraZeneca, Astellas, Eli Lilly, Pfizer, Taisho, and UCB, outside the submitted work. CHvD reports consulting fees from Kyowa Kirin, Roche, Merck, Eli Lilly, and Janssen and grants for clinical trials from Biogen, Novartis, Eli Lilly, Merck, Eisai, Janssen, Roche, Genentech, Toyama, and Biohaven, outside the submitted work. No other disclosures are reported.
